Patents for A61P 35 - Antineoplastic agents (221,099)
05/2012
05/24/2012US20120129914 Organic compositions to treat hsf1-related diseases
05/24/2012US20120129905 Pharmaceutical composition
05/24/2012US20120129904 Liquid Formulations Of Bendamustine
05/24/2012US20120129901 Triterpenoid derivatives useful as antiproliferative agents
05/24/2012US20120129897 Bis heteroaryl inhibitors of pro-matrix metalloproteinase activation
05/24/2012US20120129895 Methods of treatment
05/24/2012US20120129893 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas
05/24/2012US20120129889 Non-competitive NMDA receptor antagonists
05/24/2012US20120129886 Metalloenzyme inhibitor compounds
05/24/2012US20120129884 Photochemotherapeutic heterocyclic agents having antiproliferative and antineoplastic activity
05/24/2012US20120129881 Combinations of therapeutic agents for treating cancer
05/24/2012US20120129880 Method for determining sensitivity to irinotecan and use thereof
05/24/2012US20120129879 Compounds and Compositions for Use in Phototherapy and in Treatment of Ocular Neovascular Disease and Cancers
05/24/2012US20120129872 Fused heteroaryl inhibitors of pro-matrix metalloproteinase activation
05/24/2012US20120129871 Crystalline form of an inhibitor of MDM2/4 and p53 interaction
05/24/2012US20120129869 Phosphorylation and mutations of anaplastic lymphoma kinase as a diagnostic and therapeutic target in lung cancer
05/24/2012US20120129868 Poly (adp-ribose) polymerase (parp) inhibitors
05/24/2012US20120129867 Inhibitors of protein kinases
05/24/2012US20120129865 Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
05/24/2012US20120129864 Substituted 1-alkylcinnolin-4(1h)-one derivatives, preparation thereof and therapeutic application of same
05/24/2012US20120129862 Prokineticin 1 receptor antagonists
05/24/2012US20120129856 Compounds, compositions and methods useful for cholesterol mobilisation
05/24/2012US20120129855 Phthalazinone derivatives
05/24/2012US20120129852 Azaindazoles as kinase inhibitors and use thereof
05/24/2012US20120129851 Substituted Quinazoline and Pyrido-Pyrimidine Derivatives
05/24/2012US20120129850 Imidazolothiazole compounds for the treatment of disease
05/24/2012US20120129849 Deuterated serine-threonine protein kinase modulators
05/24/2012US20120129844 N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof
05/24/2012US20120129843 Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
05/24/2012US20120129842 Bisthiazole inhibitors of pro-matrix metalloproteinase activation
05/24/2012US20120129841 Carboline derivatives useful in the treatment of cancer and other diseases
05/24/2012US20120129837 Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof
05/24/2012US20120129831 Substituted 3-(1,2,4-Oxadiazol-5-yl)-5-Phenylpiperidines
05/24/2012US20120129830 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof and therapeutic use thereof
05/24/2012US20120129829 Novel indole modulators of s1p receptors
05/24/2012US20120129828 S1p1 receptor agonists and use thereof
05/24/2012US20120129821 Inhibitors of bruton's tyrosine kinase
05/24/2012US20120129814 Novel phosphonic acids as s1p receptor modulators
05/24/2012US20120129813 Novel compounds as receptor modulators with therapeutic utility
05/24/2012US20120129811 Tricyclic inhibitors of pro-matrix metalloproteinase activation
05/24/2012US20120129810 Combination antineoplastic therapy
05/24/2012US20120129809 Lung cancer treatment
05/24/2012US20120129797 Biodegradable stealth polymeric particles fabricated using the macromonomer approach by free radical dispersion polymerization
05/24/2012US20120129792 Agent for eliminating multidrug resistance
05/24/2012US20120129788 Phosphodiesterase 4d7 as marker for malignant, hormone-sensitive prostate cancer
05/24/2012US20120129787 Modified oligopeptides with anticancer properties and methods of obtaining them
05/24/2012US20120129779 Tubulysine derivatives
05/24/2012US20120129776 Bioactive peptides and method of using same
05/24/2012US20120129775 Antiangiogenic small molecules and methods of use
05/24/2012US20120129772 Soluble igf receptors as anti-angiogenic agents
05/24/2012US20120129178 Genomic polymorphism for predicting therapeutic response
05/24/2012US20120128793 Implantable or insertable medical device resistant to microbial growth and biofilm formation
05/24/2012US20120128787 Homeopathic Composition Comprising Hypericum Perforatum Extract And Essential Oils For The Treatment Of Neuropathic Pain
05/24/2012US20120128783 Compositions and methods for delivery of frozen particle adhesives
05/24/2012US20120128782 Multicomponent Degradable Cationic Polymers
05/24/2012US20120128771 Timed, pulsatile release systems
05/24/2012US20120128763 Lubricant for the ocular surface
05/24/2012US20120128760 Lipid compositions
05/24/2012US20120128757 Method of Manufacture of Liposome Composition
05/24/2012US20120128732 Combinations and modes of administration of therapeutic agents and combination therapy
05/24/2012US20120128727 Bacterial expression of an artificial gene for the production of crm197 and its derivatives
05/24/2012US20120128724 Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
05/24/2012US20120128723 Cancer specific antibody and cell surface proteins
05/24/2012US20120128715 Method for stimulating the immune response of newborns
05/24/2012US20120128714 Alphavirus Replicon Particles Expressing TRP2
05/24/2012US20120128705 C6orf167 peptides and vaccines containing the same
05/24/2012US20120128704 Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
05/24/2012US20120128702 Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
05/24/2012US20120128700 Constructs for delivery of therapeutic agents to neuronal cells
05/24/2012US20120128696 Methods for detecting and inhibiting angiogenesis
05/24/2012US20120128695 Teneurin c-terminal associated peptides (tcap) and methods and uses thereof
05/24/2012US20120128693 Cadherin-11 inhibitors and methods of use thereof
05/24/2012US20120128688 Anti-cxcl13 and anti-cxcr5 antibodies for the prevention and treatment of cancer and cancer cell migration
05/24/2012US20120128686 Thienopyrimidines for pharmaceutical compositions
05/24/2012US20120128681 Anti-CK8 Antibodies To Be Used For Treating Colorectal Cancers And Identifying Metastatic And/Or Invasive Phenotypes
05/24/2012US20120128678 Diagnosis and treatment of cancer using anti-tmprss11e antibody
05/24/2012US20120128677 Pancreatic cancer targets and uses thereof
05/24/2012US20120128676 Muc1 antibodies
05/24/2012US20120128674 C3b antibodies and methods for the prevention and treatment of complement-associated disorders
05/24/2012US20120128672 Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
05/24/2012US20120128670 mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY
05/24/2012US20120128668 Method of promoting bone growth by an anti-activin antibody
05/24/2012US20120128667 Pentamidine combinations for treating cancer
05/24/2012US20120128666 Methods of increasing neuronal differentiation using antibodies to lysophosphatidic acid
05/24/2012US20120128665 Preselection of subjects for therapeutic treatment based on hypoxic status
05/24/2012US20120128664 Glycosylated antibodies
05/24/2012US20120128663 Fc VARIANTS THAT EXTEND ANTIBODY HALF-LIFE
05/24/2012US20120128662 Substituted imidazoquinoxalines
05/24/2012US20120128661 Polynucleotide and polypeptide sequences involved in cancer
05/24/2012US20120128659 Agents capable of downregulating an msf-a - dependent hif-1alpha and use thereof in cancer treatment
05/24/2012US20120128657 Synthetic macrocyclic compounds and methods for treating cancer
05/24/2012US20120128656 Vaccine compositions and methods
05/24/2012US20120128651 Acute lymphoblastic leukemia (all) biomarkers
05/24/2012US20120128629 Method of labelling interferons with peg
05/24/2012US20120128626 Anti-il-6 antibodies for the treatment of anemia
05/24/2012US20120128625 Compounds, compositions, and methods for preventing metastasis of cancer cells
05/24/2012US20120128596 Fluorescent phospholipid ether compounds, compositions, and methods of use
05/24/2012US20120128591 Anti-fap antibodies and methods of use
05/24/2012US20120128587 Folate-targeted diagnostics and treatment
05/24/2012US20120128586 Method for treating chronic lymphocytic leukemia